Stockscreener 앱 받기
52.24
5.22%
-2.88
시간 외 거래:
52.24
전일 마감가:
$55.12
열려 있는:
$54.65
하루 거래량:
1.02M
Relative Volume:
1.24
시가총액:
$2.43B
수익:
$1.32B
순이익/손실:
$175.44M
주가수익비율:
14.35
EPS:
3.6395
순현금흐름:
$308.08M
1주 성능:
-5.57%
1개월 성능:
-8.86%
6개월 성능:
-27.17%
1년 성능:
-23.39%
1일 변동 폭
$51.66
$55.40
1주일 범위
$51.00
$60.14
52주 변동 폭
$47.31
$87.32
Haemonetics Corp Stock (HAE) Company Profile
명칭
Haemonetics Corp
전화
(781) 848-7100
주소
125 SUMMER STREET, BOSTON, MA
Compare HAE vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
52.24 | 2.56B | 1.32B | 175.44M | 308.08M | 3.6395 |
ABT
Abbott Laboratories
|
82.56 | 146.87B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
282.58 | 109.33B | 25.27B | 3.34B | 4.57B | 8.6358 |
MDT
Medtronic Plc
|
74.54 | 97.77B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
53.37 | 80.16B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
77.17 | 46.04B | 6.30B | 1.07B | 1.09B | 1.8406 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-15 | 다운그레이드 | Needham | Buy → Hold |
| 2025-12-11 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2025-08-11 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2025-08-08 | 재확인 | Barrington Research | Outperform |
| 2025-08-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-07-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-06-26 | 개시 | Robert W. Baird | Outperform |
| 2025-02-07 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2024-12-06 | 개시 | JP Morgan | Overweight |
| 2024-11-08 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-09-13 | 개시 | CL King | Buy |
| 2024-09-11 | 개시 | BofA Securities | Neutral |
| 2024-09-10 | 개시 | BTIG Research | Buy |
| 2024-06-12 | 업그레이드 | Needham | Hold → Buy |
| 2022-10-13 | 개시 | Mizuho | Buy |
| 2022-01-27 | 다운그레이드 | Needham | Buy → Hold |
| 2021-12-15 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-08-17 | 재개 | Raymond James | Outperform |
| 2021-06-17 | 개시 | Citigroup | Buy |
| 2021-05-14 | 업그레이드 | CJS Securities | Market Perform → Market Outperform |
| 2021-04-20 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | 다운그레이드 | CJS Securities | Market Outperform → Market Perform |
| 2021-02-03 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2021-01-21 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-11-05 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2020-05-06 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2020-03-31 | 업그레이드 | CJS Securities | Market Perform → Market Outperform |
| 2020-01-10 | 개시 | Needham | Buy |
| 2019-08-07 | 재확인 | Barrington Research | Outperform |
| 2019-05-14 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2019-05-08 | 재확인 | Barrington Research | Outperform |
| 2018-08-09 | 재확인 | Barrington Research | Outperform |
| 2018-02-07 | 재확인 | Barrington Research | Outperform |
| 2018-01-02 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2017-11-08 | 재확인 | Barrington Research | Outperform |
| 2017-08-08 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2017-07-13 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2017-02-07 | 다운그레이드 | Barrington Research | Outperform → Mkt Perform |
| 2016-11-08 | 업그레이드 | Barrington Research | Mkt Perform → Outperform |
| 2016-11-07 | 재확인 | The Benchmark Company | Hold |
| 2016-09-20 | 다운그레이드 | CJS Securities | Market Outperform → Market Perform |
| 2016-08-15 | 다운그레이드 | Sidoti | Buy → Neutral |
| 2016-08-02 | 재확인 | Jefferies | Buy |
| 2016-08-02 | 재확인 | The Benchmark Company | Hold |
모두보기
Haemonetics Corp 주식(HAE)의 최신 뉴스
TradingKey - TradingKey
Why Haemonetics Stock Is Dropping So Sharply - TipRanks
Why Haemonetics (HAE) Is Down 9.5% After Mixed FY26 Results And FY27 Outlook Reset - simplywall.st
Haemonetics Q4 Earnings Call Highlights - sharewise.com
Haemonetics Corporation (NYSE:HAE) Q4 2026 Earnings Call Transcript - Insider Monkey
A Look At Haemonetics (HAE) Valuation After Q4 Loss And Sector-Wide Medical Device Sell Off - simplywall.st
Haemonetics Earnings Call Highlights Growth Amid Headwinds - TipRanks
HAE Maintained by JP Morgan -- Price Target Lowered to $62.00 - GuruFocus
J.P. Morgan Maintains Haemonetics(HAE.US) With Hold Rating, Maintains Target Price $62 - 富途牛牛
Baird Maintains Haemonetics(HAE.US) With Buy Rating, Cuts Target Price to $67 - 富途牛牛
Haemonetics (HAE) Q4 2026 Earnings Transcript - AOL.com
Haemonetics (HAE) Reports Q4 Fiscal 2026 Revenue Growth and Posi - GuruFocus
Needham Maintains Haemonetics(HAE.US) With Hold Rating - 富途牛牛
Haemonetics (HAE) One Off Loss And Margin Hit Challenge Bullish Earnings Narrative - simplywall.st
Haemonetics Q4 FY2026 slides: earnings beat caps transformation plan - Investing.com
Earnings call transcript: Haemonetics Q4 2026 beats EPS forecast, stock surges - Investing.com
Haemonetics (HAE) Reports Q4 Earnings: What Key Metrics Have to Say - Yahoo! Finance Canada
Haemonetics reports Q4 adjusted EPS $1.29, consensus $1.27 - TipRanks
Haemonetics Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Why Haemonetics Stock Is Sliding Despite Bold Outlook - TipRanks
Q4 2026 Haemonetics Corp Earnings Call Transcript - GuruFocus
Haemonetics beats Q4 estimates, stock surges on guidance By Investing.com - Investing.com South Africa
Haemonetics beats Q4 estimates, stock surges on guidance - Investing.com
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates - Yahoo! Finance Canada
Earnings Flash (HAE) Haemonetics Posts Fiscal Q4 Net Revenue $346.4M, vs. FactSet Est of $336.8M - marketscreener.com
Earnings Flash (HAE) Haemonetics Posts Fiscal Q4 Adjusted EPS $1.29, vs. FactSet Est of $1.27 - marketscreener.com
HAEMONETICS ($HAE) Releases Q4 2026 Earnings - Quiver Quantitative
Haemonetics (NYSE:HAE) Reports Upbeat Q1 CY2026 - Yahoo Finance
Haemonetics: Fiscal Q4 Earnings Snapshot - KVUE
Haemonetics : 4th Quarter FY26 Supplemental Earnings Presentation - marketscreener.com
[8-K] HAEMONETICS CORP Reports Material Event - Stock Titan
Haemonetics puts quarterly results online before May 7 investor call - Stock Titan
Haemonetics earnings ahead: Can vascular closure rebound? By Investing.com - Investing.com Canada
Haemonetics earnings ahead: Can vascular closure rebound? - Investing.com
MSN Money - MSN
Haemonetics to Present at Bank of America 2026 Healthcare Conference - PR Newswire
Haemonetics Corp. Experiences Revision in Stock Evaluation Amid Competitive Market Landscape - Markets Mojo
Is It Time To Reassess Haemonetics (HAE) After Recent Share Price Swings? - simplywall.st
Earnings Preview: Haemonetics to Report Financial Results Pre-market on May 07 - 富途牛牛
Haemonetics Announces Upcoming Departure of Longtime Board Director - TipRanks
Haemonetics director Charles J. Dockendorff not standing for re-election - TradingView
Haemonetics (HAE) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
Vanguard reports 2.60M-share stake in Haemonetics (HAE) via Schedule 13G - Stock Titan
North Peak Capital Management, LLC's Haemonetics Corp(HAE) Holding History - GuruFocus
Will VASCADE MVP XL’s Expanded FDA Labeling Shift Haemonetics’ (HAE) Electrophysiology Growth Narrative - Yahoo Finance
Skylands Capital LLC Sells 44,894 Shares of Haemonetics Corporation $HAE - MarketBeat
Haemonetics Corp. Experiences Revision in Its Stock Evaluation Amid Market Challenges - Markets Mojo
Will VASCADE MVP XL’s Expanded FDA Labeling and Study Data Change Haemonetics' (HAE) Interventional Narrative? - simplywall.st
Riverwater Sees Haemonetics Volatility As Plasma Gains Test Execution - simplywall.st
Peregrine Capital Management LLC Invests $2.29 Million in Haemonetics Corporation $HAE - MarketBeat
New Study Highlights Safety and Efficacy Profile of Haemonetics' VASCADE MVP® XL in Large-Bore Venous Access Closure Procedures - PR Newswire
Haemonetics Corp (HAE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.34%
자본화:
|
볼륨(24시간):